ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2045

Early Preeclampsia Risk in Lupus Pregnancy: A Swedish Population-Based Register Investigation

Julia F Simard1,2, Elizabeth V. Arkema3, Cathina Nguyen4, Elisabet Svenungsson5, Anna-Karin Wikstrom6,7, Kristin Palmsten8 and Jane E. Salmon9, 1Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, 2Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 3Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 4Health Research & Policy, Stanford School of Medicine, Stanford, CA, 5Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 6Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden, 7Clinical Epidemiology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden, 8Department of Pediatrics, University of California, San Diego, La Jolla, CA, 9Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: complications, population studies, pregnancy, registries and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2016

Title: Reproductive Issues in Rheumatic Disorders

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:  Early preeclampsia is a serious pregnancy complication characterized by abnormal placentation and diffuse maternal endothelial cell dysfunction, and requires emergent delivery which may be very premature. SLE has been shown to increase the risk of preeclampsia, but little is known about the risks of early onset preeclampsia – a pregnancy morbidity associated with stroke, placental abruptions, and perinatal death.

Methods:  Using national population-based Swedish registers we identified women with SLE (≥2 visits with corresponding ICD codes) and without SLE who gave birth to singleton infants 2001-2012 in the Swedish Medical Birth Register. Comparators without SLE were drawn from the general population. Preeclampsia was defined using date of first corresponding diagnosis during pregnancy to define early onset (<34 weeks). The association between early preeclampsia and maternal SLE was estimated by multivariable-adjusted modified Poisson models for first, subsequent, and all births. BMI, age, smoking, and pregestational hypertension and diabetes were included as potential confounders. We used ICD-10- coded visit and heparin dispensing during pregnancy from the Prescribed Drug Register (2006-2012) as a proxy for antiphospholipid syndrome (APS).Preeclampsia history was adjusted for in analyses of subsequent and all births. We investigated effect modification by pregestational hypertension, examined residual confounding by APS and misclassification of preeclampsia due to lupus nephritis.

Results: There were 742 births to women with SLE (343 first births) and 10484 births to women from the general population (4443 first births). Compared to the general population, SLE was associated with a significantly increased risk of early preeclampsia for all, first, and subsequent births [RR=7.3, (95% CI=4.5, 11.9), mvar-adj, all births]. Adjustment for APS proxy attenuated the association (RR=3.7, 95% CI=1.7, 7.9), but SLE remained significantly associated with early preeclampsia. Findings were similar among women without pregestational hypertension, a strong risk factor for early preeclampsia, as well as in the absence of recent nephrology care. RRs for early preeclampsia were smaller, but significant, for subsequent births compared to first and all births [RR=2.8, (95% CI=1.2, 6.4) subsequent].

Conclusion:  Women with SLE are at increased risk of preeclampsia before 34 weeks gestation, and importantly, this increased risk may be independent of pregestational hypertension, APS, BMI, or smoking. Traditional risk factors alone may not explain the increased risk of early preeclampsia among women with SLE for first, subsequent, or any birth. Women with SLE during pregnancy should continue to be monitored carefully for early preeclampsia and future research is needed to identify what non-traditional preeclampsia factors might be causing this serious outcome.


Disclosure: J. F. Simard, None; E. V. Arkema, None; C. Nguyen, None; E. Svenungsson, None; A. K. Wikstrom, None; K. Palmsten, None; J. E. Salmon, None.

To cite this abstract in AMA style:

Simard JF, Arkema EV, Nguyen C, Svenungsson E, Wikstrom AK, Palmsten K, Salmon JE. Early Preeclampsia Risk in Lupus Pregnancy: A Swedish Population-Based Register Investigation [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/early-preeclampsia-risk-in-lupus-pregnancy-a-swedish-population-based-register-investigation/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/early-preeclampsia-risk-in-lupus-pregnancy-a-swedish-population-based-register-investigation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology